SCN9A and erythromelalgia: The present results document another gain-of-function mutation of NaV1.7 that is associated with painful symptoms in humans, in a family with onset of erythromelalgia's symptoms in the second decade, and add to the data pointing to this channel as a target for therapeutic intervention for the treatment of chronic pain.